{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:13:30Z","timestamp":1785420810901,"version":"3.56.0"},"posted":{"date-parts":[[2026,3,1]]},"group-title":"Immunology","reference-count":30,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["23-1579"],"award-info":[{"award-number":["23-1579"]}],"id":[{"id":"https:\/\/ror.org\/05d8ft347","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["5U54DA016511-18"],"award-info":[{"award-number":["5U54DA016511-18"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Colorectal cancer (CRC) is the leading cause of cancer mortality in young adults, with chemoresistance and metastatic progression severely limiting treatment options. MUC4, a membrane-bound mucin normally confined to the apical surface of epithelial cells, becomes aberrantly overexpressed across the tumor cell membrane in CRC and other cancer types, promoting cancer survival, immune evasion, and metastasis. Therefore, MUC4 is a promising candidate for the development of targeted therapies. We detected MUC4 cell surface expression in a panel of human CRC cell lines. We engineered MUC4-specific chimeric antigen receptor (CAR) T cells and evaluated their activity against methotrexate-resistant MUC4-expressing human CRC cell lines HT29-MTX and T84. MUC4 CAR-T cells efficiently eliminated HT29-MTX and T84 cells\n                  <jats:italic>in vitro<\/jats:italic>\n                  and delayed HT29-MTX subcutaneous tumor growth\n                  <jats:italic>in vivo<\/jats:italic>\n                  . Importantly, MUC4 CAR-T cell treatment significantly reduced tumor burden and improved survival in a highly aggressive and lethal CRC model, intraperitoneal HT29-MTX CRC metastatic dissemination in NSG mice. Mouse necropsies revealed no off-target\n                  <jats:italic>in vivo<\/jats:italic>\n                  toxicities associated with MUC4 CAR-T cell therapy. Altogether, our findings establish MUC4 as an important and clinically relevant CAR-T cell target and demonstrate therapeutic efficacy of MUC4 CAR-T cell therapy for invasive CRC, a setting where chemotherapy typically fails. MUC4-targeted CAR-T cell therapy has the potential to fill a critical treatment gap for patients with chemoresistant and invasive CRC and may extend to other MUC4-expressing solid tumors.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Statement of Priority<\/jats:title>\n                  <jats:p>Colorectal cancer is increasingly diagnosed in younger individuals, a trend accompanied by a higher prevalence of aggressive and chemotherapy-resistant disease. Despite advances in systemic therapy, outcomes for patients with refractory or metastatic colorectal cancer remain poor, underscoring a critical unmet clinical need. CAR-T cell therapy offers a mechanism to selectively target tumor cells that evade conventional treatments and may thus be particularly valuable in mucinous, chemotherapy-resistant subsets. Developing effective CAR-T strategies for new targets in colorectal carcinoma, such as MUC4, is an urgent priority in this era of rising early-onset disease.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.26.708339","type":"posted-content","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T03:15:16Z","timestamp":1772421316000},"source":"Crossref","is-referenced-by-count":0,"title":["MUC4-targeted CAR-T Cells Restrain Chemotherapy-resistant Colorectal Cancer"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-0204","authenticated-orcid":false,"given":"Avik","family":"Chattopadhyay","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3247-6734","authenticated-orcid":false,"given":"Erin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8851-7080","authenticated-orcid":false,"given":"Anna M.","family":"Tingler","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"},{"name":"Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9746-0764","authenticated-orcid":false,"given":"Kristi L.","family":"Helke","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-9932","authenticated-orcid":false,"given":"Melinda A.","family":"Engevik","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"},{"name":"Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-9866","authenticated-orcid":false,"given":"Leonardo M.R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026030405401677000_2026.02.26.708339v1.1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2025.9147","article-title":"Colorectal Cancer Incidence in US Adults After Recommendations for Earlier Screening","volume":"334","year":"2025","journal-title":"JAMA"},{"key":"2026030405401677000_2026.02.26.708339v1.2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026030405401677000_2026.02.26.708339v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1251"},{"key":"2026030405401677000_2026.02.26.708339v1.4","doi-asserted-by":"crossref","first-page":"1356913","DOI":"10.3389\/fimmu.2024.1356913","article-title":"MUC1 and MUC16: critical for immune modulation in cancer therapeutics","volume":"15","year":"2024","journal-title":"Front Immunol"},{"key":"2026030405401677000_2026.02.26.708339v1.5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13122"},{"key":"2026030405401677000_2026.02.26.708339v1.6","doi-asserted-by":"crossref","first-page":"e0287768","DOI":"10.1371\/journal.pone.0287768","article-title":"Genetic variants of MUC4 are associated with susceptibility to and mortality of colorectal cancer and exhibit synergistic effects with LDL-C levels","volume":"18","year":"2023","journal-title":"PLoS One"},{"key":"2026030405401677000_2026.02.26.708339v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25095"},{"key":"2026030405401677000_2026.02.26.708339v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026030405401677000_2026.02.26.708339v1.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04547-4"},{"key":"2026030405401677000_2026.02.26.708339v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.009"},{"key":"2026030405401677000_2026.02.26.708339v1.11","doi-asserted-by":"crossref","first-page":"101385","DOI":"10.1016\/j.omtm.2024.101385","article-title":"High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells","volume":"32","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026030405401677000_2026.02.26.708339v1.12","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3593-3_15"},{"key":"2026030405401677000_2026.02.26.708339v1.13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-0716-3593-3_16","article-title":"How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy","volume":"2748","year":"2024","journal-title":"Methods Mol Biol"},{"key":"2026030405401677000_2026.02.26.708339v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114994"},{"key":"2026030405401677000_2026.02.26.708339v1.15","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.108.3.1275"},{"key":"2026030405401677000_2026.02.26.708339v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biolcel.2003.12.005"},{"key":"2026030405401677000_2026.02.26.708339v1.17","doi-asserted-by":"publisher","DOI":"10.1042\/bj2670491"},{"key":"2026030405401677000_2026.02.26.708339v1.18","doi-asserted-by":"crossref","unstructured":"Young J , Edwards J , Park JH . The epidemiology, current evidence and controversies in diagnosis and management of patients with colorectal peritoneal metastases. Surgeon 2025","DOI":"10.1016\/j.surge.2025.11.001"},{"key":"2026030405401677000_2026.02.26.708339v1.19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO-24-02081","article-title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","volume":"43","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026030405401677000_2026.02.26.708339v1.20","doi-asserted-by":"publisher","DOI":"10.1159\/000453594"},{"key":"2026030405401677000_2026.02.26.708339v1.21","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","article-title":"Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1","volume":"72","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026030405401677000_2026.02.26.708339v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9857"},{"key":"2026030405401677000_2026.02.26.708339v1.23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1200\/JCO.1999.17.5.1535","article-title":"Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells","volume":"17","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026030405401677000_2026.02.26.708339v1.24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729260"},{"key":"2026030405401677000_2026.02.26.708339v1.25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.str.2024.04.011","article-title":"Structural elucidation of the mesothelin-mucin-16\/CA125 interaction","volume":"32","year":"2024","journal-title":"Structure"},{"key":"2026030405401677000_2026.02.26.708339v1.26","doi-asserted-by":"crossref","first-page":"eadx9371","DOI":"10.1126\/sciadv.adx9371","article-title":"Optimally engineered HLA\/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumors","volume":"12","year":"2026","journal-title":"Sci Adv"},{"key":"2026030405401677000_2026.02.26.708339v1.27","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","article-title":"Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming","volume":"37","year":"2025","journal-title":"Cell Metab"},{"key":"2026030405401677000_2026.02.26.708339v1.28","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.125"},{"key":"2026030405401677000_2026.02.26.708339v1.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09924-4"},{"key":"2026030405401677000_2026.02.26.708339v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800646"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.26.708339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:40:24Z","timestamp":1772631624000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.26.708339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.64898\/2026.02.26.708339","relation":{},"subject":[],"published":{"date-parts":[[2026,3,1]]},"subtype":"preprint"}}